DE2620649C3 - Immunologisches Adjuvans - Google Patents

Immunologisches Adjuvans

Info

Publication number
DE2620649C3
DE2620649C3 DE2620649A DE2620649A DE2620649C3 DE 2620649 C3 DE2620649 C3 DE 2620649C3 DE 2620649 A DE2620649 A DE 2620649A DE 2620649 A DE2620649 A DE 2620649A DE 2620649 C3 DE2620649 C3 DE 2620649C3
Authority
DE
Germany
Prior art keywords
neuraminidase
antigens
antigen
adjuvant
neuraminic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE2620649A
Other languages
German (de)
English (en)
Other versions
DE2620649B2 (de
DE2620649A1 (de
Inventor
Juergen Dr. 3551 Lahntal Knop
Hans-Harald Dr. Sedlacek
Friedrich Robert Dr. Seiler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics GmbH Germany
Original Assignee
Behringwerke AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke AG filed Critical Behringwerke AG
Priority to DE2620649A priority Critical patent/DE2620649C3/de
Priority to CH571377A priority patent/CH630807A5/de
Priority to NL7704998A priority patent/NL7704998A/xx
Priority to IT23350/77A priority patent/IT1075545B/it
Priority to GB19294/77A priority patent/GB1569003A/en
Priority to NZ184039A priority patent/NZ184039A/xx
Priority to LU77295A priority patent/LU77295A1/xx
Priority to IL52048A priority patent/IL52048A/xx
Priority to IE951/77A priority patent/IE45145B1/en
Priority to AU25033/77A priority patent/AU512240B2/en
Priority to FR7714243A priority patent/FR2350847A1/fr
Priority to CA278,034A priority patent/CA1077841A/en
Priority to DK204277A priority patent/DK204277A/da
Priority to AT0332577A priority patent/AT363590B/de
Priority to BE177483A priority patent/BE854512A/xx
Priority to JP5416377A priority patent/JPS52136914A/ja
Publication of DE2620649A1 publication Critical patent/DE2620649A1/de
Publication of DE2620649B2 publication Critical patent/DE2620649B2/de
Application granted granted Critical
Publication of DE2620649C3 publication Critical patent/DE2620649C3/de
Priority to US06/406,531 priority patent/US4510129A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE2620649A 1976-05-11 1976-05-11 Immunologisches Adjuvans Expired DE2620649C3 (de)

Priority Applications (17)

Application Number Priority Date Filing Date Title
DE2620649A DE2620649C3 (de) 1976-05-11 1976-05-11 Immunologisches Adjuvans
CH571377A CH630807A5 (de) 1976-05-11 1977-05-06 Verfahren zur herstellung eines antiserums.
NL7704998A NL7704998A (nl) 1976-05-11 1977-05-06 Werkwijze voor de bereiding en toepassing van een middel ter stimulering van de mimmunol- -ogische reactiviteit.
GB19294/77A GB1569003A (en) 1976-05-11 1977-05-09 Immunostimulating agent
NZ184039A NZ184039A (en) 1976-05-11 1977-05-09 Immunostimulating agent comprising an antigen and neuraminidase
LU77295A LU77295A1 (cg-RX-API-DMAC7.html) 1976-05-11 1977-05-09
IL52048A IL52048A (en) 1976-05-11 1977-05-09 Immunostimulating agent
IT23350/77A IT1075545B (it) 1976-05-11 1977-05-09 Agente immuno-stimolante
IE951/77A IE45145B1 (en) 1976-05-11 1977-05-10 Immunostimulating agent
FR7714243A FR2350847A1 (fr) 1976-05-11 1977-05-10 Agent immunostimulant
CA278,034A CA1077841A (en) 1976-05-11 1977-05-10 Immunostimulating agent
DK204277A DK204277A (da) 1976-05-11 1977-05-10 Immunstimulerende middel
AT0332577A AT363590B (de) 1976-05-11 1977-05-10 Verfahren zur stimulierung der immunologischen reaktivitaet eines antigens
AU25033/77A AU512240B2 (en) 1976-05-11 1977-05-10 Immunostimulating agent
BE177483A BE854512A (fr) 1976-05-11 1977-05-11 Agent immunostimulant
JP5416377A JPS52136914A (en) 1976-05-11 1977-05-11 Immune stimulating agent
US06/406,531 US4510129A (en) 1976-05-11 1982-08-09 Immunostimulating agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2620649A DE2620649C3 (de) 1976-05-11 1976-05-11 Immunologisches Adjuvans

Publications (3)

Publication Number Publication Date
DE2620649A1 DE2620649A1 (de) 1977-11-17
DE2620649B2 DE2620649B2 (de) 1980-03-13
DE2620649C3 true DE2620649C3 (de) 1980-11-06

Family

ID=5977559

Family Applications (1)

Application Number Title Priority Date Filing Date
DE2620649A Expired DE2620649C3 (de) 1976-05-11 1976-05-11 Immunologisches Adjuvans

Country Status (17)

Country Link
US (1) US4510129A (cg-RX-API-DMAC7.html)
JP (1) JPS52136914A (cg-RX-API-DMAC7.html)
AT (1) AT363590B (cg-RX-API-DMAC7.html)
AU (1) AU512240B2 (cg-RX-API-DMAC7.html)
BE (1) BE854512A (cg-RX-API-DMAC7.html)
CA (1) CA1077841A (cg-RX-API-DMAC7.html)
CH (1) CH630807A5 (cg-RX-API-DMAC7.html)
DE (1) DE2620649C3 (cg-RX-API-DMAC7.html)
DK (1) DK204277A (cg-RX-API-DMAC7.html)
FR (1) FR2350847A1 (cg-RX-API-DMAC7.html)
GB (1) GB1569003A (cg-RX-API-DMAC7.html)
IE (1) IE45145B1 (cg-RX-API-DMAC7.html)
IL (1) IL52048A (cg-RX-API-DMAC7.html)
IT (1) IT1075545B (cg-RX-API-DMAC7.html)
LU (1) LU77295A1 (cg-RX-API-DMAC7.html)
NL (1) NL7704998A (cg-RX-API-DMAC7.html)
NZ (1) NZ184039A (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI790483A7 (fi) * 1978-02-16 1979-08-17 Science Union & Cie Foerfarande foer framstaellning av ett enzym av bakteriellt ursprung och farmaceutiska kompositioner innehaollande detsamma
US4729893A (en) * 1984-12-26 1988-03-08 Robert L. Letcher Enteric encapsulation of ancrod for oral administration
GB9018061D0 (en) * 1990-08-17 1990-10-03 Wellcome Found Compositions for vaccines
US20030108927A1 (en) * 2000-04-03 2003-06-12 Kathryn Leishman Compositions and methods for the prevention, treatment and detection of tuberculosis and other diseases
US7078165B2 (en) * 2003-03-27 2006-07-18 Institut Pasteur Method for modulating Nod1 activity, use of a MTP related molecule for modulating Nod1 activity, and therapeutic applications thereof
GB0307989D0 (en) * 2003-04-07 2003-05-14 Mcewen Lab Ltd Therapeutic composition
AU2013323472B2 (en) * 2012-09-28 2018-07-05 Ellis KLINE Glycosidase regimen for treatment of infectious disease
JP7187024B2 (ja) 2016-07-01 2022-12-12 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 標的化された細胞表面編集のための複合体
EP3735458A4 (en) 2018-01-03 2022-04-27 Palleon Pharmaceuticals Inc. RECOMBINANT HUMAN SIALIDASES, SIALIDASE FUSION PROTEINS AND METHODS OF USE THEREOF

Also Published As

Publication number Publication date
ATA332577A (de) 1981-01-15
IL52048A0 (en) 1977-07-31
DE2620649B2 (de) 1980-03-13
CA1077841A (en) 1980-05-20
AT363590B (de) 1981-08-10
AU2503377A (en) 1978-11-16
US4510129A (en) 1985-04-09
GB1569003A (en) 1980-06-11
IT1075545B (it) 1985-04-22
IE45145L (en) 1977-11-11
DK204277A (da) 1977-11-12
LU77295A1 (cg-RX-API-DMAC7.html) 1977-12-13
IE45145B1 (en) 1982-06-30
FR2350847B1 (cg-RX-API-DMAC7.html) 1980-02-29
NL7704998A (nl) 1977-11-15
DE2620649A1 (de) 1977-11-17
IL52048A (en) 1980-11-30
BE854512A (fr) 1977-11-14
AU512240B2 (en) 1980-10-02
JPS52136914A (en) 1977-11-16
FR2350847A1 (fr) 1977-12-09
JPS624371B2 (cg-RX-API-DMAC7.html) 1987-01-30
CH630807A5 (de) 1982-07-15
NZ184039A (en) 1980-04-28

Similar Documents

Publication Publication Date Title
DE69620001T2 (de) Impfstoffe gegen grippe
DE69128782T2 (de) Oraler an der oberfläche von erythrozyten gebundene antigene beinhaltender impfstoff
AT408615B (de) Neue influenzavirus-impfstoffzusammensetzung
EP0331102B1 (de) Virusmodifizierte Tumorvakzinen für die Immuntherapie von Tumormetastasen
DE68911019T2 (de) Kombiniertes Hepatitis A- und B-Vakzin mit Adjuvans.
EP1144001B1 (de) Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
DE69533673T2 (de) Behandlung und prävention von helicobacter-infektionen
EP0304786A2 (de) Intranasale Impfung von Pferden mit inaktivierten Mikroorganismen oder antigenem Material
DE2620649C3 (de) Immunologisches Adjuvans
DE69528074T2 (de) Chitosan induzierte verstärkung
DE3786301T2 (de) Kombinierter Impfstoff.
DE2714665A1 (de) Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung
DE3122669A1 (de) "verfahren zur herstellung von neuen mutanten von herpes simplex-viren typ 1 und typ 2"
DE3034238A1 (de) Impfstoff zur bekaempfung der newcastle-krankheit und verfahren zur herstellung derselben
DE1792256C3 (de) Oral applizierbare, polyvalente Impfstoffe gegen lokale Darminfektionen
DE1617545A1 (de) Antigenfreie Vaccine
DE69116155T2 (de) Neuramidase und glulaktoseoxidase als vaccinadjuvans
DE1492243C3 (de) Injizierbare Impfstoffe
DE2200376A1 (de) Vaccine gegen Streptococcus equi. und Verfahren zu deren Herstellung
DD298884A5 (de) Impfstoffe gegen virale antigene und verfahren zu ihrer herstellung
DE1902590C2 (de) Verwendung einer Immunribonucleinsäure (IRNS) zum Immunisieren lebender Tiere
DE2161344C3 (de) Herstellung von Virusstämmen, welche die natürlichen Abwehrmechanismen eines Wirtsorganismus stimulieren, ohne dabei gleichzeitig antigen zu wirken und Arzneimittel zur Prophylaxe und Behandlung von viralen und bakteriellen Infektionen des Menschen und der Tiere, einen solchen Virusstamm enthaltend
DE2034118A1 (en) Xenogenic nucleic acids for enhancing antigenicity - of peptides and proteins
JP3944266B2 (ja) 鳥類用経口アジュバント及び鳥類の免疫応答増強法
DE2111120C3 (de) Verfahren zur Herstellung von Rubella-Virus-Hämagglutinationsantigen

Legal Events

Date Code Title Description
OD Request for examination
C3 Grant after two publication steps (3rd publication)
8339 Ceased/non-payment of the annual fee